Header Logo

Connection

MARY ESTES to Norovirus

Back to Details
This is a "connection" page, showing publications MARY ESTES has written about Norovirus.
MARY ESTES
Connection Strength
18.244
Norovirus
  1. Norovirus replication, host interactions and vaccine advances. Nat Rev Microbiol. 2025 Jun; 23(6):385-401.
    View in: PubMed
    Score: 0.714
  2. Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody Levels With GI.1 Histo-Blood Group Antigen-Blocking Antibody Levels. J Infect Dis. 2024 Dec 16; 230(6):1376-1379.
    View in: PubMed
    Score: 0.709
  3. Insights into human norovirus cultivation in human intestinal enteroids. mSphere. 2024 Nov 21; 9(11):e0044824.
    View in: PubMed
    Score: 0.701
  4. Bile acid-sensitive human norovirus strains are susceptible to sphingosine-1-phosphate receptor 2 inhibition. J Virol. 2024 Jul 23; 98(7):e0202023.
    View in: PubMed
    Score: 0.685
  5. A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies. J Infect Dis. 2024 May 15; 229(5):1402-1407.
    View in: PubMed
    Score: 0.681
  6. Standardization of an antiviral pipeline for human norovirus in human intestinal enteroids demonstrates nitazoxanide has no to weak antiviral activity. Antimicrob Agents Chemother. 2023 10 18; 67(10):e0063623.
    View in: PubMed
    Score: 0.653
  7. CLIC and membrane wound repair pathways enable pandemic norovirus entry and infection. Nat Commun. 2023 02 28; 14(1):1148.
    View in: PubMed
    Score: 0.626
  8. Antiviral Activity of Olanexidine-Containing Hand Rub against Human Noroviruses. mBio. 2022 04 26; 13(2):e0284821.
    View in: PubMed
    Score: 0.586
  9. Bile Goes Viral. Viruses. 2021 05 27; 13(6).
    View in: PubMed
    Score: 0.554
  10. New Insights and Enhanced Human Norovirus Cultivation in Human Intestinal Enteroids. mSphere. 2021 01 27; 6(1).
    View in: PubMed
    Score: 0.542
  11. Human norovirus exhibits strain-specific sensitivity to host interferon pathways in human intestinal enteroids. Proc Natl Acad Sci U S A. 2020 09 22; 117(38):23782-23793.
    View in: PubMed
    Score: 0.528
  12. Comparison of Microneutralization and Histo-Blood Group Antigen-Blocking Assays for Functional Norovirus Antibody Detection. J Infect Dis. 2020 02 18; 221(5):739-743.
    View in: PubMed
    Score: 0.508
  13. Bile acids and ceramide overcome the entry restriction for GII.3 human norovirus replication in human intestinal enteroids. Proc Natl Acad Sci U S A. 2020 01 21; 117(3):1700-1710.
    View in: PubMed
    Score: 0.503
  14. Human Norovirus Cultivation in Nontransformed Stem Cell-Derived Human Intestinal Enteroid Cultures: Success and Challenges. Viruses. 2019 07 11; 11(7).
    View in: PubMed
    Score: 0.487
  15. Human noroviruses: recent advances in a 50-year history. Curr Opin Infect Dis. 2018 10; 31(5):422-432.
    View in: PubMed
    Score: 0.461
  16. Replication of Human Norovirus RNA in Mammalian Cells Reveals Lack of Interferon Response. J Virol. 2016 10 01; 90(19):8906-23.
    View in: PubMed
    Score: 0.400
  17. Replication of human noroviruses in stem cell-derived human enteroids. Science. 2016 09 23; 353(6306):1387-1393.
    View in: PubMed
    Score: 0.399
  18. Mapping broadly reactive norovirus genogroup I and II monoclonal antibodies. Clin Vaccine Immunol. 2015 Feb; 22(2):168-77.
    View in: PubMed
    Score: 0.353
  19. Plasmid-based human norovirus reverse genetics system produces reporter-tagged progeny virus containing infectious genomic RNA. Proc Natl Acad Sci U S A. 2014 Sep 23; 111(38):E4043-52.
    View in: PubMed
    Score: 0.348
  20. Structural basis of glycan interaction in gastroenteric viral pathogens. Curr Opin Virol. 2014 Aug; 7:119-27.
    View in: PubMed
    Score: 0.345
  21. Epidemiology of human noroviruses and updates on vaccine development. Curr Opin Gastroenterol. 2014 Jan; 30(1):25-33.
    View in: PubMed
    Score: 0.332
  22. Norovirus vaccine development: next steps. Expert Rev Vaccines. 2012 Sep; 11(9):1023-5.
    View in: PubMed
    Score: 0.303
  23. An inside job: subversion of the host secretory pathway by intestinal pathogens. Curr Opin Infect Dis. 2010 Oct; 23(5):464-9.
    View in: PubMed
    Score: 0.265
  24. Norovirus gastroenteritis. N Engl J Med. 2009 Oct 29; 361(18):1776-85.
    View in: PubMed
    Score: 0.249
  25. Noroviruses everywhere: has something changed? Curr Opin Infect Dis. 2006 Oct; 19(5):467-74.
    View in: PubMed
    Score: 0.201
  26. The epidemiologic and clinical importance of norovirus infection. Gastroenterol Clin North Am. 2006 Jun; 35(2):275-90, viii.
    View in: PubMed
    Score: 0.196
  27. Identification of Genogroup I and Genogroup II broadly reactive epitopes on the norovirus capsid. J Virol. 2005 Jun; 79(12):7402-9.
    View in: PubMed
    Score: 0.183
  28. Human intestinal enteroids for evaluating the persistence of infectious human norovirus in raw surface freshwater. Sci Total Environ. 2025 Feb 25; 966:178707.
    View in: PubMed
    Score: 0.179
  29. Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors. J Virol. 2025 Feb 25; 99(2):e0175724.
    View in: PubMed
    Score: 0.179
  30. 2'-Fucosyllactose inhibits human norovirus replication in human intestinal enteroids. J Virol. 2025 Feb 25; 99(2):e0093824.
    View in: PubMed
    Score: 0.178
  31. RNA-dependent RNA polymerase of predominant human norovirus forms liquid-liquid phase condensates as viral replication factories. Sci Adv. 2024 Dec 20; 10(51):eadp9333.
    View in: PubMed
    Score: 0.177
  32. Norovirus disease: changing epidemiology and host susceptibility factors. Trends Microbiol. 2004 Jun; 12(6):279-87.
    View in: PubMed
    Score: 0.171
  33. Laboratory efforts to cultivate noroviruses. J Gen Virol. 2004 Jan; 85(Pt 1):79-87.
    View in: PubMed
    Score: 0.166
  34. A single nanobody neutralizes multiple epochally evolving human noroviruses by modulating capsid plasticity. Nat Commun. 2023 10 16; 14(1):6516.
    View in: PubMed
    Score: 0.164
  35. Clinical and In Vitro Evidence Favoring Immunoglobulin Treatment of a Chronic Norovirus Infection in a Patient With Common Variable Immunodeficiency. J Infect Dis. 2022 11 11; 226(10):1781-1789.
    View in: PubMed
    Score: 0.153
  36. Use of Human Intestinal Enteroids to Evaluate Persistence of Infectious Human Norovirus in Seawater. Emerg Infect Dis. 2022 07; 28(7):1475-1479.
    View in: PubMed
    Score: 0.150
  37. Evaluation of Heat Inactivation of Human Norovirus in Freshwater Clams Using Human Intestinal Enteroids. Viruses. 2022 05 10; 14(5).
    View in: PubMed
    Score: 0.148
  38. Atomic structure of the predominant GII.4 human norovirus capsid reveals novel stability and plasticity. Nat Commun. 2022 03 10; 13(1):1241.
    View in: PubMed
    Score: 0.146
  39. Norovirus Protease Structure and Antivirals Development. Viruses. 2021 10 14; 13(10).
    View in: PubMed
    Score: 0.142
  40. Broadly cross-reactive human antibodies that inhibit genogroup I and II noroviruses. Nat Commun. 2021 07 14; 12(1):4320.
    View in: PubMed
    Score: 0.140
  41. A Millifluidic Perfusion Cassette for Studying the Pathogenesis of Enteric Infections Using Ex-Vivo Organoids. Ann Biomed Eng. 2021 Apr; 49(4):1233-1244.
    View in: PubMed
    Score: 0.135
  42. High-Resolution Mapping of Human Norovirus Antigens via Genomic Phage Display Library Selections and Deep Sequencing. J Virol. 2020 12 09; 95(1).
    View in: PubMed
    Score: 0.134
  43. Histo-blood group antigens of glycosphingolipids predict susceptibility of human intestinal enteroids to norovirus infection. J Biol Chem. 2020 11 20; 295(47):15974-15987.
    View in: PubMed
    Score: 0.132
  44. CD300lf is the primary physiologic receptor of murine norovirus but not human norovirus. PLoS Pathog. 2020 04; 16(4):e1008242.
    View in: PubMed
    Score: 0.128
  45. Use of Human Intestinal Enteroids to Detect ?Human Norovirus Infectivity. Emerg Infect Dis. 2019 09; 25(9):1730-1735.
    View in: PubMed
    Score: 0.123
  46. GII.4 Norovirus Protease Shows pH-Sensitive Proteolysis with a Unique Arg-His Pairing in the Catalytic Site. J Virol. 2019 03 15; 93(6).
    View in: PubMed
    Score: 0.119
  47. Human Intestinal Enteroids: New Models to Study Gastrointestinal Virus Infections. Methods Mol Biol. 2019; 1576:229-247.
    View in: PubMed
    Score: 0.117
  48. Human Monoclonal Antibodies That Neutralize Pandemic GII.4?Noroviruses. Gastroenterology. 2018 12; 155(6):1898-1907.
    View in: PubMed
    Score: 0.115
  49. Human Norovirus Replication in Human Intestinal Enteroids as Model to Evaluate Virus Inactivation. Emerg Infect Dis. 2018 08; 24(8):1453-1464.
    View in: PubMed
    Score: 0.114
  50. Viral gastroenteritis. Lancet. 2018 07 14; 392(10142):175-186.
    View in: PubMed
    Score: 0.113
  51. Prospects and Challenges in the Development of a Norovirus Vaccine. Clin Ther. 2017 Aug; 39(8):1537-1549.
    View in: PubMed
    Score: 0.106
  52. Human Sera Collected between 1979 and 2010 Possess Blocking-Antibody Titers to Pandemic GII.4 Noroviruses Isolated over Three Decades. J Virol. 2017 07 15; 91(14).
    View in: PubMed
    Score: 0.106
  53. Identification and Characterization of Single-Chain Antibodies that Specifically Bind GI Noroviruses. PLoS One. 2017; 12(1):e0170162.
    View in: PubMed
    Score: 0.102
  54. Deep sequencing of phage-displayed peptide libraries reveals sequence motif that detects norovirus. Protein Eng Des Sel. 2017 Feb; 30(2):129-139.
    View in: PubMed
    Score: 0.102
  55. Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody. Proc Natl Acad Sci U S A. 2016 10 04; 113(40):E5830-E5837.
    View in: PubMed
    Score: 0.100
  56. Detection of human norovirus in intestinal biopsies from immunocompromised transplant patients. J Gen Virol. 2016 09; 97(9):2291-2300.
    View in: PubMed
    Score: 0.099
  57. Antiviral targets of human noroviruses. Curr Opin Virol. 2016 06; 18:117-25.
    View in: PubMed
    Score: 0.098
  58. Norovirus Gastroenteritis in a Birth Cohort in Southern India. PLoS One. 2016; 11(6):e0157007.
    View in: PubMed
    Score: 0.098
  59. Serological Responses to a Norovirus Nonstructural Fusion Protein after Vaccination and Infection. Clin Vaccine Immunol. 2016 02; 23(2):181-3.
    View in: PubMed
    Score: 0.095
  60. Norovirus Antigen Detection with a Combination of Monoclonal and Single-Chain Antibodies. J Clin Microbiol. 2015 Dec; 53(12):3916-8.
    View in: PubMed
    Score: 0.094
  61. Serological Correlates of Protection against a GII.4 Norovirus. Clin Vaccine Immunol. 2015 Aug; 22(8):923-9.
    View in: PubMed
    Score: 0.092
  62. Sensitive detection of norovirus using phage nanoparticle reporters in lateral-flow assay. PLoS One. 2015; 10(5):e0126571.
    View in: PubMed
    Score: 0.091
  63. Noroviruses as a Cause of Diarrhea in Immunocompromised Pediatric Hematopoietic Stem Cell and Solid Organ Transplant Recipients. Am J Transplant. 2015 Jul; 15(7):1874-81.
    View in: PubMed
    Score: 0.090
  64. Characterization of cross-reactive norovirus-specific monoclonal antibodies. Clin Vaccine Immunol. 2015 Feb; 22(2):160-7.
    View in: PubMed
    Score: 0.088
  65. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect Dis. 2015 Mar 15; 211(6):870-8.
    View in: PubMed
    Score: 0.087
  66. Identification of human single-chain antibodies with broad reactivity for noroviruses. Protein Eng Des Sel. 2014 Oct; 27(10):339-49.
    View in: PubMed
    Score: 0.086
  67. Structural analysis of determinants of histo-blood group antigen binding specificity in genogroup I noroviruses. J Virol. 2014 Jun; 88(11):6168-80.
    View in: PubMed
    Score: 0.084
  68. Seroepidemiology of norovirus-associated travelers' diarrhea. J Travel Med. 2014 Jan-Feb; 21(1):6-11.
    View in: PubMed
    Score: 0.083
  69. Exposure to human and bovine noroviruses in a birth cohort in southern India from 2002 to 2006. J Clin Microbiol. 2013 Jul; 51(7):2391-5.
    View in: PubMed
    Score: 0.079
  70. Identification and characterization of a peptide affinity reagent for detection of noroviruses in clinical samples. J Clin Microbiol. 2013 Jun; 51(6):1803-8.
    View in: PubMed
    Score: 0.079
  71. Lack of norovirus replication and histo-blood group antigen expression in 3-dimensional intestinal epithelial cells. Emerg Infect Dis. 2013 Mar; 19(3):431-8.
    View in: PubMed
    Score: 0.078
  72. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med. 2011 Dec 08; 365(23):2178-87.
    View in: PubMed
    Score: 0.072
  73. Structural analysis of histo-blood group antigen binding specificity in a norovirus GII.4 epidemic variant: implications for epochal evolution. J Virol. 2011 Sep; 85(17):8635-45.
    View in: PubMed
    Score: 0.070
  74. Adsorption and aggregation properties of norovirus GI and GII virus-like particles demonstrate differing responses to solution chemistry. Environ Sci Technol. 2011 Jan 15; 45(2):520-6.
    View in: PubMed
    Score: 0.067
  75. Antibody prevalence and titer to norovirus (genogroup II) correlate with secretor (FUT2) but not with ABO phenotype or Lewis (FUT3) genotype. J Infect Dis. 2006 Nov 15; 194(10):1422-7.
    View in: PubMed
    Score: 0.050
  76. Evolutionary trace residues in noroviruses: importance in receptor binding, antigenicity, virion assembly, and strain diversity. J Virol. 2005 Jan; 79(1):554-68.
    View in: PubMed
    Score: 0.044
  77. Cross-reactivity among several recombinant calicivirus virus-like particles (VLPs) with monoclonal antibodies obtained from mice immunized orally with one type of VLP. J Clin Microbiol. 2002 Jul; 40(7):2459-65.
    View in: PubMed
    Score: 0.037
  78. Glycan Recognition in Human Norovirus Infections. Viruses. 2021 10 14; 13(10).
    View in: PubMed
    Score: 0.036
  79. Genetic Manipulation of Human Intestinal Enteroids Demonstrates the Necessity of a Functional Fucosyltransferase 2 Gene for Secretor-Dependent Human Norovirus Infection. mBio. 2020 03 17; 11(2).
    View in: PubMed
    Score: 0.032
  80. B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine. Clin Vaccine Immunol. 2017 May; 24(5).
    View in: PubMed
    Score: 0.026
  81. Correlates of Protection against Norovirus Infection and Disease-Where Are We Now, Where Do We Go? PLoS Pathog. 2016 04; 12(4):e1005334.
    View in: PubMed
    Score: 0.024
  82. Inter- and intragenus structural variations in caliciviruses and their functional implications. J Virol. 2004 Jun; 78(12):6469-79.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.